KR20110011676A - 항-ＰｉｒＢ 항체 - Google Patents

항-ＰｉｒＢ 항체 Download PDF

Info

Publication number
KR20110011676A
KR20110011676A KR1020107027786A KR20107027786A KR20110011676A KR 20110011676 A KR20110011676 A KR 20110011676A KR 1020107027786 A KR1020107027786 A KR 1020107027786A KR 20107027786 A KR20107027786 A KR 20107027786A KR 20110011676 A KR20110011676 A KR 20110011676A
Authority
KR
South Korea
Prior art keywords
antibody
ser
leu
pirb
gly
Prior art date
Application number
KR1020107027786A
Other languages
English (en)
Korean (ko)
Inventor
자스빈더 아타왈
마크 테시어-라빈
얀 우
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/208,883 external-priority patent/US20100047232A1/en
Priority claimed from US12/316,130 external-priority patent/US20090232794A1/en
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20110011676A publication Critical patent/KR20110011676A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020107027786A 2008-05-13 2009-05-13 항-ＰｉｒＢ 항체 KR20110011676A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US5294908P 2008-05-13 2008-05-13
US61/052,949 2008-05-13
US12/208,883 US20100047232A1 (en) 2006-11-14 2008-09-11 Modulators of neuronal regeneration
US12/208,883 2008-09-11
US12/316,130 US20090232794A1 (en) 2007-12-11 2008-12-09 Modulators of neuronal regeneration
US12/316,130 2008-12-09

Publications (1)

Publication Number Publication Date
KR20110011676A true KR20110011676A (ko) 2011-02-08

Family

ID=41319035

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107027786A KR20110011676A (ko) 2008-05-13 2009-05-13 항-ＰｉｒＢ 항체

Country Status (15)

Country Link
EP (1) EP2291405A1 (zh)
JP (1) JP2011523359A (zh)
KR (1) KR20110011676A (zh)
CN (1) CN102089327A (zh)
AR (1) AR071777A1 (zh)
AU (1) AU2009246443A1 (zh)
BR (1) BRPI0912769A2 (zh)
CA (1) CA2723430A1 (zh)
IL (1) IL209129A0 (zh)
MX (1) MX2010012299A (zh)
PE (1) PE20091969A1 (zh)
RU (1) RU2010150754A (zh)
TW (1) TW200950808A (zh)
WO (1) WO2009140361A1 (zh)
ZA (1) ZA201007976B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
ES2870717T3 (es) * 2012-04-17 2021-10-27 Mayo Found Medical Education & Res Anticuerpos humanos y secuencias de unión específicas del mismo para su uso en accidente cerebrovascular e isquemia y condiciones isquémicas
CN103130898B (zh) * 2013-01-28 2014-03-26 中国人民解放军第四军医大学 Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用
AU2018389111A1 (en) 2017-12-22 2020-06-18 Jounce Therapeutics, Inc. Antibodies to LILRB2
JP7411627B2 (ja) 2018-07-09 2024-01-11 ファイヴ プライム セラピューティクス インク Ｉｌｔ４と結合する抗体
CN109439661B (zh) * 2018-10-22 2020-10-23 西安医学院 抑制pirB表达的短发卡shRNA、慢病毒及其应用
CN116589581A (zh) 2020-05-01 2023-08-15 恩格姆生物制药公司 Ilt结合剂和其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453540A4 (en) * 2001-11-14 2005-06-01 Immunex Corp MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
EP1981522B1 (en) * 2006-01-23 2012-09-12 President and Fellows of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration

Also Published As

Publication number Publication date
MX2010012299A (es) 2010-12-06
CN102089327A (zh) 2011-06-08
PE20091969A1 (es) 2010-01-15
EP2291405A1 (en) 2011-03-09
BRPI0912769A2 (pt) 2015-10-13
ZA201007976B (en) 2012-02-29
JP2011523359A (ja) 2011-08-11
AR071777A1 (es) 2010-07-14
AU2009246443A1 (en) 2009-11-19
CA2723430A1 (en) 2009-11-19
WO2009140361A1 (en) 2009-11-19
RU2010150754A (ru) 2012-06-20
TW200950808A (en) 2009-12-16
IL209129A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
US20240309097A2 (en) Methods of use of anti-sortilin antibodies for treating a disease, disorder, or injury
US7384632B2 (en) Agonist anti-trk-C monoclonal antibodies
KR20110011676A (ko) 항-ＰｉｒＢ 항체
US7943329B2 (en) Modulators of neuronal regeneration
KR20100018523A (ko) ＣＲＩｇ 길항제
US20090232794A1 (en) Modulators of neuronal regeneration
US20090285803A1 (en) ANTI-PirB ANTIBODIES
US20100047232A1 (en) Modulators of neuronal regeneration
EA043015B1 (ru) Антитела против сортилина и способы их применения
ZA200210086B (en) Agonist Anti-TRK-C monoclonal antibodies.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid